Pdl Biopharma Inc (PDLI) 2.99 $PDLI
PDL BioPharma Announces the Successful Conclusion of its Debt Financing Agreement with Paradigm Spine
PR Newswire - Mon Aug 29, 6:00AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of $54.7 million as well as accrued interest and a prepayment fee. In February 2014, PDL entered into a credit agreement with Paradigm Spine in which it made available up to $75.0 million of debt financing with a five-year term, and initially provided $50.0 million, net of fees. PDL subsequently provided an additional $4.0 million in October 2015 as part of an amendment to the credit agreement.
PDLI: 2.99 (+0.02)
PDL BioPharma Announces Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:05PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2016 including:
PDLI: 2.99 (+0.02)
PDL BioPharma Announces Elimination of Quarterly Cash Dividend
PR Newswire - Thu Aug 04, 3:02PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend.
PDLI: 2.99 (+0.02)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 10.12 (-0.07), PDLI: 2.99 (+0.02)
PDL BioPharma to Announce Second Quarter 2016 Financial Results on August 4, 2016
PR Newswire - Thu Jul 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 2.99 (+0.02)
PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:30 p.m. EDT.
PDLI: 2.99 (+0.02)
PDL BioPharma Agrees to Equity Investment in Noden Pharma
Zacks Equity Research - Zacks Investment Research - Wed May 25, 9:02AM CDT
PDL BioPharma (PDLI) announced that it has committed to an equity investment in Noden Pharma to acquire global rights to Tekturna and Tekturna HCT.
PFE: 34.77 (+0.09), BMY: 56.35 (-0.41), PDLI: 2.99 (+0.02), NVS: 79.38 (+1.11)
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PR Newswire - Tue May 24, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product's active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had estimated global sales in 2015 of $154 million. The transactions are expected to close upon Hart-Scott-Rodino regulatory approval or expiration of the related waiting period. PDL's equity investment will ultimately result in an 88% equity interest in Noden. Given this anticipated majority ownership by PDL, the financial statements of Noden will be consolidated with PDL, which is expected to be immediately accretive to PDL's cash earnings.
PDLI: 2.99 (+0.02), NVS: 79.38 (+1.11)
PDL BioPharma Announces First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including:
PDLI: 2.99 (+0.02)
PDL BioPharma Announces 2016 Second Quarter Dividend
PR Newswire - Wed May 04, 3:01PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016. The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter dividend payment.
PDLI: 2.99 (+0.02)
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 2.99 (+0.02)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.75 (-0.02), XNCR: 20.35 (-1.08), PDLI: 2.99 (+0.02)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.28 (-0.02), CLVS: 23.40 (-0.19), RLYP: 31.98 (-0.01), PDLI: 2.99 (+0.02)
PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 2.99 (+0.02)
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 2.99 (+0.02)
PDL BioPharma Announces 2016 First Quarter Dividend
PR Newswire - Mon Feb 01, 3:02PM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016. The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter dividend payment.
PDLI: 2.99 (+0.02)
3 High-Risk Dividend Stocks I'd Avoid
Andrés Cardenal, Tyler Crowe, and George Budwell, The Motley Fool - Motley Fool - Sat Jan 30, 8:20AM CST
Most investors love dividend stocks, and for good reasons. Statistical studies have proven time and again that investing in companies with strong dividends can be a powerful strategy to achieve superior returns from your portfolio over the long...
PM: 101.77 (+1.15), WMB: 28.40 (+0.25), ETE: 17.84 (+0.03), MO: 66.88 (+0.56), WPZ: 38.47 (+0.60), PDLI: 2.99 (+0.02)
Stock to Watch: PDL BioPharma Down 5.4% (PDLI)
Comtex SmarTrend(R) - Mon Jan 11, 12:48PM CST
PDL BioPharma (NASDAQ
DLI) is one of today's worst performing low-priced stocks, down 5.4% to $3.09 on 1.0x average daily volume. Thus far today, PDL BioPharma has traded 2.4 million shares, vs. average volume of 2.4 million shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.4%) and underperformed the S&P 500 (-5.4% to the S&P's -0.8%) during today's trading.
PDLI: 2.99 (+0.02)
2 Cheap Stocks Not Worth Their (Incredibly Low) Price
Motley Fool Staff - Motley Fool - Tue Jan 05, 2:43PM CST
If you're thinking of investing in stocks under $5, even in mid- and large-cap companies, make sure you're getting a deal instead of low-value paper. As you might expect, a lot of cheap shares are cheap for a reason. In this clip of Industry...
MNKD: 0.74 (unch), PDLI: 2.99 (+0.02)
PDL BioPharma Announces the Successful Conclusion of its Debt Financing Agreement with Paradigm Spine
PR Newswire - Mon Aug 29, 6:00AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of $54.7 million as well as accrued interest and a prepayment fee. In February 2014, PDL entered into a credit agreement with Paradigm Spine in which it made available up to $75.0 million of debt financing with a five-year term, and initially provided $50.0 million, net of fees. PDL subsequently provided an additional $4.0 million in October 2015 as part of an amendment to the credit agreement.
PDLI: 2.99 (+0.02)
PDL BioPharma Announces Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:05PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2016 including:
PDLI: 2.99 (+0.02)
PDL BioPharma Announces Elimination of Quarterly Cash Dividend
PR Newswire - Thu Aug 04, 3:02PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend.
PDLI: 2.99 (+0.02)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 10.12 (-0.07), PDLI: 2.99 (+0.02)
PDL BioPharma to Announce Second Quarter 2016 Financial Results on August 4, 2016
PR Newswire - Thu Jul 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 2.99 (+0.02)
PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:30 p.m. EDT.
PDLI: 2.99 (+0.02)
PDL BioPharma Agrees to Equity Investment in Noden Pharma
Zacks Equity Research - Zacks Investment Research - Wed May 25, 9:02AM CDT
PDL BioPharma (PDLI) announced that it has committed to an equity investment in Noden Pharma to acquire global rights to Tekturna and Tekturna HCT.
PFE: 34.77 (+0.09), BMY: 56.35 (-0.41), PDLI: 2.99 (+0.02), NVS: 79.38 (+1.11)
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PR Newswire - Tue May 24, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product's active ingredient is aliskiren, which is indicated for the treatment of hypertension. The drug was previously marketed by Novartis and had estimated global sales in 2015 of $154 million. The transactions are expected to close upon Hart-Scott-Rodino regulatory approval or expiration of the related waiting period. PDL's equity investment will ultimately result in an 88% equity interest in Noden. Given this anticipated majority ownership by PDL, the financial statements of Noden will be consolidated with PDL, which is expected to be immediately accretive to PDL's cash earnings.
PDLI: 2.99 (+0.02), NVS: 79.38 (+1.11)
PDL BioPharma Announces First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including:
PDLI: 2.99 (+0.02)
PDL BioPharma Announces 2016 Second Quarter Dividend
PR Newswire - Wed May 04, 3:01PM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016. The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter dividend payment.
PDLI: 2.99 (+0.02)
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 28, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
PDLI: 2.99 (+0.02)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.75 (-0.02), XNCR: 20.35 (-1.08), PDLI: 2.99 (+0.02)
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.28 (-0.02), CLVS: 23.40 (-0.19), RLYP: 31.98 (-0.01), PDLI: 2.99 (+0.02)
PDL BioPharma, Inc. Shares Just Fell Off a Cliff -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 02, 3:30PM CST
What: Shares of PDL BioPharma , a biotech company that focuses on purchasing and developing royalty-based patented assets, sank as much as 13% after the company outlined its new dividend policy. So what: According to PDL BioPharma's press...
PDLI: 2.99 (+0.02)
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
PDLI: 2.99 (+0.02)
PDL BioPharma Announces 2016 First Quarter Dividend
PR Newswire - Mon Feb 01, 3:02PM CST
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016. The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter dividend payment.
PDLI: 2.99 (+0.02)
3 High-Risk Dividend Stocks I'd Avoid
Andrés Cardenal, Tyler Crowe, and George Budwell, The Motley Fool - Motley Fool - Sat Jan 30, 8:20AM CST
Most investors love dividend stocks, and for good reasons. Statistical studies have proven time and again that investing in companies with strong dividends can be a powerful strategy to achieve superior returns from your portfolio over the long...
PM: 101.77 (+1.15), WMB: 28.40 (+0.25), ETE: 17.84 (+0.03), MO: 66.88 (+0.56), WPZ: 38.47 (+0.60), PDLI: 2.99 (+0.02)
Stock to Watch: PDL BioPharma Down 5.4% (PDLI)
Comtex SmarTrend(R) - Mon Jan 11, 12:48PM CST
PDL BioPharma (NASDAQ
DLI) is one of today's worst performing low-priced stocks, down 5.4% to $3.09 on 1.0x average daily volume. Thus far today, PDL BioPharma has traded 2.4 million shares, vs. average volume of 2.4 million shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.4%) and underperformed the S&P 500 (-5.4% to the S&P's -0.8%) during today's trading. PDLI: 2.99 (+0.02)
2 Cheap Stocks Not Worth Their (Incredibly Low) Price
Motley Fool Staff - Motley Fool - Tue Jan 05, 2:43PM CST
If you're thinking of investing in stocks under $5, even in mid- and large-cap companies, make sure you're getting a deal instead of low-value paper. As you might expect, a lot of cheap shares are cheap for a reason. In this clip of Industry...
MNKD: 0.74 (unch), PDLI: 2.99 (+0.02)
